#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=While most nAChR agonists and antagonists binding at ACh orthosteric sites are basic molecules with at least one ionizable N , there are exceptions , including lophotoxin , the neonicotinoids and some recently synthesized pyrimidine agonists .
3-1	15-20	While	_	_	_	_
3-2	21-25	most	abstract[4]	new[4]	coref	3-32[14_4]
3-3	26-31	nAChR	abstract|abstract[4]	new|new[4]	coref	14-9
3-4	32-40	agonists	abstract[4]	new[4]	_	_
3-5	41-44	and	_	_	_	_
3-6	45-56	antagonists	substance	new	coref	3-13[8_0]
3-7	57-64	binding	_	_	_	_
3-8	65-67	at	_	_	_	_
3-9	68-71	ACh	place|place[7]	new|new[7]	coref|coref|coref|coref	8-27|10-32[83_7]|8-27|10-32[83_7]
3-10	72-83	orthosteric	place[7]	new[7]	_	_
3-11	84-89	sites	place[7]	new[7]	_	_
3-12	90-93	are	_	_	_	_
3-13	94-99	basic	substance[8]	giv[8]	_	_
3-14	100-109	molecules	substance[8]	giv[8]	_	_
3-15	110-114	with	substance[8]	giv[8]	_	_
3-16	115-117	at	substance[8]|abstract[9]	giv[8]|new[9]	_	_
3-17	118-123	least	substance[8]|abstract[9]	giv[8]|new[9]	_	_
3-18	124-127	one	substance[8]|abstract[9]	giv[8]|new[9]	_	_
3-19	128-137	ionizable	substance[8]|abstract[9]	giv[8]|new[9]	_	_
3-20	138-139	N	substance[8]|abstract[9]	giv[8]|new[9]	_	_
3-21	140-141	,	_	_	_	_
3-22	142-147	there	_	_	_	_
3-23	148-151	are	_	_	_	_
3-24	152-162	exceptions	abstract[10]	new[10]	_	_
3-25	163-164	,	abstract[10]	new[10]	_	_
3-26	165-174	including	abstract[10]	new[10]	_	_
3-27	175-185	lophotoxin	abstract[10]|substance	new[10]|new	_	_
3-28	186-187	,	abstract[10]	new[10]	_	_
3-29	188-191	the	abstract[10]|substance[12]	new[10]|new[12]	_	_
3-30	192-206	neonicotinoids	abstract[10]|substance[12]	new[10]|new[12]	_	_
3-31	207-210	and	abstract[10]	new[10]	_	_
3-32	211-215	some	abstract[10]|abstract[14]	new[10]|giv[14]	coref	14-9[114_14]
3-33	216-224	recently	abstract[10]|abstract[14]	new[10]|giv[14]	_	_
3-34	225-236	synthesized	abstract[10]|abstract[14]	new[10]|giv[14]	_	_
3-35	237-247	pyrimidine	abstract[10]|abstract|abstract[14]	new[10]|new|giv[14]	_	_
3-36	248-256	agonists	abstract[10]|abstract[14]	new[10]|giv[14]	_	_
3-37	257-258	.	_	_	_	_

#Text=To optimize a molecule to serve as a drug or selective molecular probe of some receptor it is important to identify the form in which it interacts optimally with its target .
4-1	259-261	To	_	_	_	_
4-2	262-270	optimize	_	_	_	_
4-3	271-272	a	object[15]	new[15]	_	_
4-4	273-281	molecule	object[15]	new[15]	_	_
4-5	282-284	to	_	_	_	_
4-6	285-290	serve	_	_	_	_
4-7	291-293	as	_	_	_	_
4-8	294-295	a	_	_	_	_
4-9	296-300	drug	_	_	_	_
4-10	301-303	or	_	_	_	_
4-11	304-313	selective	_	_	_	_
4-12	314-323	molecular	_	_	_	_
4-13	324-329	probe	_	_	_	_
4-14	330-332	of	_	_	_	_
4-15	333-337	some	substance[16]	new[16]	coref	5-46[0_16]
4-16	338-346	receptor	substance[16]	new[16]	_	_
4-17	347-349	it	abstract	new	cata	4-17[0_18]
4-18	350-352	is	_	_	_	_
4-19	353-362	important	_	_	_	_
4-20	363-365	to	abstract[18]	new[18]	ana	4-26[0_18]
4-21	366-374	identify	abstract[18]	new[18]	_	_
4-22	375-378	the	abstract[18]|substance[19]	new[18]|new[19]	coref	5-10[28_19]
4-23	379-383	form	abstract[18]|substance[19]	new[18]|new[19]	_	_
4-24	384-386	in	_	_	_	_
4-25	387-392	which	_	_	_	_
4-26	393-395	it	abstract	giv	ana	4-30
4-27	396-405	interacts	_	_	_	_
4-28	406-415	optimally	_	_	_	_
4-29	416-420	with	_	_	_	_
4-30	421-424	its	abstract|abstract[22]	giv|new[22]	coref|coref	5-44[37_22]|5-44[37_22]
4-31	425-431	target	abstract[22]	new[22]	_	_
4-32	432-433	.	_	_	_	_

#Text=In the case of anabaseine , our identification of the cyclic iminium form as the most active ( and possibly the only ) form suggests that structural modifications that enhance the basicity of its tetrahydropyridyl nitrogen will enhance potency and possibly selectivity for the intended receptor target .
5-1	434-436	In	_	_	_	_
5-2	437-440	the	abstract[23]	new[23]	_	_
5-3	441-445	case	abstract[23]	new[23]	_	_
5-4	446-448	of	abstract[23]	new[23]	_	_
5-5	449-459	anabaseine	abstract[23]|substance	new[23]|new	coref	8-18
5-6	460-461	,	_	_	_	_
5-7	462-465	our	person|abstract[26]	acc|new[26]	ana|ana	12-60|12-60
5-8	466-480	identification	abstract[26]	new[26]	_	_
5-9	481-483	of	abstract[26]	new[26]	_	_
5-10	484-487	the	abstract[26]|substance[28]	new[26]|giv[28]	ana	5-34[0_28]
5-11	488-494	cyclic	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-12	495-502	iminium	abstract[26]|object|substance[28]	new[26]|new|giv[28]	coref	8-15
5-13	503-507	form	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-14	508-510	as	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-15	511-514	the	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-16	515-519	most	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-17	520-526	active	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-18	527-528	(	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-19	529-532	and	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-20	533-541	possibly	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-21	542-545	the	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-22	546-550	only	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-23	551-552	)	abstract[26]|substance[28]	new[26]|giv[28]	_	_
5-24	553-557	form	_	_	_	_
5-25	558-566	suggests	_	_	_	_
5-26	567-571	that	_	_	_	_
5-27	572-582	structural	abstract[29]	new[29]	_	_
5-28	583-596	modifications	abstract[29]	new[29]	_	_
5-29	597-601	that	_	_	_	_
5-30	602-609	enhance	_	_	_	_
5-31	610-613	the	abstract[30]	new[30]	_	_
5-32	614-622	basicity	abstract[30]	new[30]	_	_
5-33	623-625	of	abstract[30]	new[30]	_	_
5-34	626-629	its	abstract[30]|substance|substance[33]	new[30]|giv|new[33]	coref|coref	8-13[60_0]|8-13[60_0]
5-35	630-647	tetrahydropyridyl	abstract[30]|abstract|substance[33]	new[30]|new|new[33]	_	_
5-36	648-656	nitrogen	abstract[30]|substance[33]	new[30]|new[33]	_	_
5-37	657-661	will	_	_	_	_
5-38	662-669	enhance	_	_	_	_
5-39	670-677	potency	abstract	new	coref	23-14[157_0]
5-40	678-681	and	_	_	_	_
5-41	682-690	possibly	abstract[35]	new[35]	_	_
5-42	691-702	selectivity	abstract[35]	new[35]	_	_
5-43	703-706	for	abstract[35]	new[35]	_	_
5-44	707-710	the	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-45	711-719	intended	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-46	720-728	receptor	abstract[35]|substance|abstract[37]	new[35]|giv|giv[37]	_	_
5-47	729-735	target	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-48	736-737	.	_	_	_	_

#Text=In fact , a major improvement in stability occurs with addition at the 3-position of the tetrahydropyridyl ring of an electron-conjugated system containing an aromatic ring , as in 3-(4-dimethylaminobenzylidene)-anabaseine or 3-(2,4-dimethoxybenzylidene)-anabaseine , also called GTS-21 .
6-1	738-740	In	_	_	_	_
6-2	741-745	fact	_	_	_	_
6-3	746-747	,	_	_	_	_
6-4	748-749	a	abstract[38]	new[38]	_	_
6-5	750-755	major	abstract[38]	new[38]	_	_
6-6	756-767	improvement	abstract[38]	new[38]	_	_
6-7	768-770	in	abstract[38]	new[38]	_	_
6-8	771-780	stability	abstract[38]|abstract	new[38]|new	_	_
6-9	781-787	occurs	_	_	_	_
6-10	788-792	with	_	_	_	_
6-11	793-801	addition	abstract[40]	new[40]	_	_
6-12	802-804	at	abstract[40]	new[40]	_	_
6-13	805-808	the	abstract[40]|substance[41]	new[40]|new[41]	_	_
6-14	809-819	3-position	abstract[40]|substance[41]	new[40]|new[41]	_	_
6-15	820-822	of	abstract[40]|substance[41]	new[40]|new[41]	_	_
6-16	823-826	the	abstract[40]|substance[41]|object[42]	new[40]|new[41]|new[42]	coref	6-24[44_42]
6-17	827-844	tetrahydropyridyl	abstract[40]|substance[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-18	845-849	ring	abstract[40]|substance[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-19	850-852	of	abstract[40]|substance[41]|object[42]	new[40]|new[41]|new[42]	_	_
6-20	853-855	an	abstract[40]|substance[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-21	856-875	electron-conjugated	abstract[40]|substance[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-22	876-882	system	abstract[40]|substance[41]|object[42]|abstract[43]	new[40]|new[41]|new[42]|new[43]	_	_
6-23	883-893	containing	_	_	_	_
6-24	894-896	an	object[44]	giv[44]	coref	7-7[0_44]
6-25	897-905	aromatic	object[44]	giv[44]	_	_
6-26	906-910	ring	object[44]	giv[44]	_	_
6-27	911-912	,	_	_	_	_
6-28	913-915	as	_	_	_	_
6-29	916-918	in	_	_	_	_
6-30	919-960	3-(4-dimethylaminobenzylidene)-anabaseine	_	_	_	_
6-31	961-963	or	_	_	_	_
6-32	964-1003	3-(2,4-dimethoxybenzylidene)-anabaseine	substance	new	_	_
6-33	1004-1005	,	_	_	_	_
6-34	1006-1010	also	_	_	_	_
6-35	1011-1017	called	_	_	_	_
6-36	1018-1024	GTS-21	abstract	new	_	_
6-37	1025-1026	.	_	_	_	_

#Text=These anabaseine derivatives do not undergo ring opening ( hydrolysis of the imine bond ) under physiological conditions , due to their extended π electron conjugation .
7-1	1027-1032	These	substance[47]	new[47]	ana	7-22[0_47]
7-2	1033-1043	anabaseine	substance[47]	new[47]	_	_
7-3	1044-1055	derivatives	substance[47]	new[47]	_	_
7-4	1056-1058	do	_	_	_	_
7-5	1059-1062	not	_	_	_	_
7-6	1063-1070	undergo	_	_	_	_
7-7	1071-1075	ring	object|event[49]	giv|new[49]	coref|coref	24-15[164_0]|24-15[164_0]
7-8	1076-1083	opening	event[49]	new[49]	_	_
7-9	1084-1085	(	_	_	_	_
7-10	1086-1096	hydrolysis	abstract[50]	new[50]	_	_
7-11	1097-1099	of	abstract[50]	new[50]	_	_
7-12	1100-1103	the	abstract[50]|abstract[52]	new[50]|new[52]	coref	24-20[166_52]
7-13	1104-1109	imine	abstract[50]|abstract|abstract[52]	new[50]|new|new[52]	_	_
7-14	1110-1114	bond	abstract[50]|abstract[52]	new[50]|new[52]	_	_
7-15	1115-1116	)	_	_	_	_
7-16	1117-1122	under	_	_	_	_
7-17	1123-1136	physiological	abstract[53]	new[53]	_	_
7-18	1137-1147	conditions	abstract[53]	new[53]	_	_
7-19	1148-1149	,	abstract[53]	new[53]	_	_
7-20	1150-1153	due	abstract[53]	new[53]	_	_
7-21	1154-1156	to	_	_	_	_
7-22	1157-1162	their	substance|abstract[57]	giv|new[57]	ana|ana	8-3[0_57]|8-3[0_57]
7-23	1163-1171	extended	abstract[57]	new[57]	_	_
7-24	1172-1173	π	abstract|abstract[57]	new|new[57]	_	_
7-25	1174-1182	electron	substance|abstract[57]	new|new[57]	_	_
7-26	1183-1194	conjugation	abstract[57]	new[57]	_	_
7-27	1195-1196	.	_	_	_	_

#Text=Previously , it was assumed ( but not experimentally tested ) that the cyclic iminium form of anabaseine is the one which binds avidly to the ACh binding site in nAChRs .
8-1	1197-1207	Previously	_	_	_	_
8-2	1208-1209	,	_	_	_	_
8-3	1210-1212	it	abstract	giv	_	_
8-4	1213-1216	was	_	_	_	_
8-5	1217-1224	assumed	_	_	_	_
8-6	1225-1226	(	_	_	_	_
8-7	1227-1230	but	_	_	_	_
8-8	1231-1234	not	_	_	_	_
8-9	1235-1249	experimentally	_	_	_	_
8-10	1250-1256	tested	_	_	_	_
8-11	1257-1258	)	_	_	_	_
8-12	1259-1263	that	_	_	_	_
8-13	1264-1267	the	substance[60]	giv[60]	coref	9-1[67_60]
8-14	1268-1274	cyclic	substance[60]	giv[60]	_	_
8-15	1275-1282	iminium	object|substance[60]	giv|giv[60]	coref	10-18[77_0]
8-16	1283-1287	form	substance[60]	giv[60]	_	_
8-17	1288-1290	of	substance[60]	giv[60]	_	_
8-18	1291-1301	anabaseine	substance[60]|substance	giv[60]|giv	coref	10-7[75_0]
8-19	1302-1304	is	_	_	_	_
8-20	1305-1308	the	event[62]	new[62]	_	_
8-21	1309-1312	one	event[62]	new[62]	_	_
8-22	1313-1318	which	_	_	_	_
8-23	1319-1324	binds	_	_	_	_
8-24	1325-1331	avidly	_	_	_	_
8-25	1332-1334	to	_	_	_	_
8-26	1335-1338	the	place[65]	new[65]	coref	24-32[171_65]
8-27	1339-1342	ACh	abstract|place[65]	giv|new[65]	_	_
8-28	1343-1350	binding	object|place[65]	new|new[65]	coref	10-8
8-29	1351-1355	site	place[65]	new[65]	_	_
8-30	1356-1358	in	place[65]	new[65]	_	_
8-31	1359-1365	nAChRs	place[65]|place	new[65]|new	coref	12-50
8-32	1366-1367	.	_	_	_	_

#Text=This form was modeled to fit into a muscle type homology model .
9-1	1368-1372	This	substance[67]	giv[67]	_	_
9-2	1373-1377	form	substance[67]	giv[67]	_	_
9-3	1378-1381	was	_	_	_	_
9-4	1382-1389	modeled	_	_	_	_
9-5	1390-1392	to	_	_	_	_
9-6	1393-1396	fit	_	_	_	_
9-7	1397-1401	into	_	_	_	_
9-8	1402-1403	a	object[71]	new[71]	_	_
9-9	1404-1410	muscle	object|object[71]	new|new[71]	_	_
9-10	1411-1415	type	abstract|object[71]	new|new[71]	_	_
9-11	1416-1424	homology	abstract|object[71]	new|new[71]	_	_
9-12	1425-1430	model	object[71]	new[71]	_	_
9-13	1431-1432	.	_	_	_	_

#Text=The crystal structure of the molluscan acetylcholine binding protein binding anabaseine actually was derived from crystals containing both the cyclic iminium and the open-chain monocationic form of anabaseine occupying some of the five identical binding sites .
10-1	1433-1436	The	abstract[72]	new[72]	coref	12-33[95_72]
10-2	1437-1444	crystal	abstract[72]	new[72]	_	_
10-3	1445-1454	structure	abstract[72]	new[72]	_	_
10-4	1455-1457	of	abstract[72]	new[72]	_	_
10-5	1458-1461	the	abstract[72]	new[72]	_	_
10-6	1462-1471	molluscan	abstract[72]	new[72]	_	_
10-7	1472-1485	acetylcholine	abstract[72]|substance[75]	new[72]|giv[75]	coref	10-28[0_75]
10-8	1486-1493	binding	abstract[72]|object|substance[75]	new[72]|giv|giv[75]	coref	10-35
10-9	1494-1501	protein	abstract[72]|substance|substance[75]	new[72]|new|giv[75]	_	_
10-10	1502-1509	binding	abstract[72]|substance[75]	new[72]|giv[75]	_	_
10-11	1510-1520	anabaseine	abstract[72]|substance[75]	new[72]|giv[75]	_	_
10-12	1521-1529	actually	_	_	_	_
10-13	1530-1533	was	_	_	_	_
10-14	1534-1541	derived	_	_	_	_
10-15	1542-1546	from	_	_	_	_
10-16	1547-1555	crystals	object	new	coref	12-5[90_0]
10-17	1556-1566	containing	_	_	_	_
10-18	1567-1571	both	object[77]|abstract[78]	giv[77]|new[78]	ana|coref|ana|coref	10-30[81_78]|11-2[84_77]|10-30[81_78]|11-2[84_77]
10-19	1572-1575	the	object[77]|abstract[78]	giv[77]|new[78]	_	_
10-20	1576-1582	cyclic	object[77]|abstract[78]	giv[77]|new[78]	_	_
10-21	1583-1590	iminium	object[77]|abstract[78]	giv[77]|new[78]	_	_
10-22	1591-1594	and	abstract[78]	new[78]	_	_
10-23	1595-1598	the	abstract[78]|substance[79]	new[78]|new[79]	coref	12-29[94_79]
10-24	1599-1609	open-chain	abstract[78]|substance[79]	new[78]|new[79]	_	_
10-25	1610-1622	monocationic	abstract[78]|substance[79]	new[78]|new[79]	_	_
10-26	1623-1627	form	abstract[78]|substance[79]	new[78]|new[79]	_	_
10-27	1628-1630	of	abstract[78]|substance[79]	new[78]|new[79]	_	_
10-28	1631-1641	anabaseine	abstract[78]|substance[79]|substance	new[78]|new[79]|giv	coref	12-44
10-29	1642-1651	occupying	_	_	_	_
10-30	1652-1656	some	abstract[81]	giv[81]	_	_
10-31	1657-1659	of	abstract[81]	giv[81]	_	_
10-32	1660-1663	the	abstract[81]|place[83]	giv[81]|giv[83]	coref	12-16[92_83]
10-33	1664-1668	five	abstract[81]|place[83]	giv[81]|giv[83]	_	_
10-34	1669-1678	identical	abstract[81]|place[83]	giv[81]|giv[83]	_	_
10-35	1679-1686	binding	abstract[81]|object|place[83]	giv[81]|giv|giv[83]	coref	24-35
10-36	1687-1692	sites	abstract[81]|place[83]	giv[81]|giv[83]	_	_
10-37	1693-1694	.	_	_	_	_

#Text=Unlike the cyclic iminium , the ammonium-ketone form ammonium group did not insert into the “ aromatic box . ”
11-1	1695-1701	Unlike	_	_	_	_
11-2	1702-1705	the	object[84]	giv[84]	coref	23-21[0_84]
11-3	1706-1712	cyclic	object[84]	giv[84]	_	_
11-4	1713-1720	iminium	object[84]	giv[84]	_	_
11-5	1721-1722	,	_	_	_	_
11-6	1723-1726	the	person[86]	new[86]	_	_
11-7	1727-1742	ammonium-ketone	person[86]	new[86]	_	_
11-8	1743-1747	form	person[86]	new[86]	_	_
11-9	1748-1756	ammonium	object|person[86]	new|new[86]	_	_
11-10	1757-1762	group	person[86]	new[86]	_	_
11-11	1763-1766	did	_	_	_	_
11-12	1767-1770	not	_	_	_	_
11-13	1771-1777	insert	_	_	_	_
11-14	1778-1782	into	_	_	_	_
11-15	1783-1786	the	object[87]	new[87]	coref	24-28[168_87]
11-16	1787-1788	“	object[87]	new[87]	_	_
11-17	1789-1797	aromatic	object[87]	new[87]	_	_
11-18	1798-1801	box	object[87]	new[87]	_	_
11-19	1802-1803	.	_	_	_	_
11-20	1804-1805	”	_	_	_	_

#Text=In the preparation of the AChBP-anabaseine crystals very high anabaseine concentrations were used so that most of the five sites would be occupied ; therefore the presence of the ammonium-ketone form in the crystal structure does not necessarily indicate that this form of anabaseine would bind to AChBPs and nAChRs at the low concentrations of anabaseine that occur in our in vitro functional and binding studies .
12-1	1806-1808	In	_	_	_	_
12-2	1809-1812	the	abstract[88]	new[88]	_	_
12-3	1813-1824	preparation	abstract[88]	new[88]	_	_
12-4	1825-1827	of	abstract[88]	new[88]	_	_
12-5	1828-1831	the	abstract[88]|object[90]	new[88]|giv[90]	_	_
12-6	1832-1848	AChBP-anabaseine	abstract[88]|abstract|object[90]	new[88]|new|giv[90]	_	_
12-7	1849-1857	crystals	abstract[88]|object[90]	new[88]|giv[90]	_	_
12-8	1858-1862	very	animal[91]	new[91]	coref	30-20[210_91]
12-9	1863-1867	high	animal[91]	new[91]	_	_
12-10	1868-1878	anabaseine	animal[91]	new[91]	_	_
12-11	1879-1893	concentrations	animal[91]	new[91]	_	_
12-12	1894-1898	were	_	_	_	_
12-13	1899-1903	used	_	_	_	_
12-14	1904-1906	so	_	_	_	_
12-15	1907-1911	that	_	_	_	_
12-16	1912-1916	most	place[92]	giv[92]	_	_
12-17	1917-1919	of	place[92]	giv[92]	_	_
12-18	1920-1923	the	place[92]	giv[92]	_	_
12-19	1924-1928	five	place[92]	giv[92]	_	_
12-20	1929-1934	sites	place[92]	giv[92]	_	_
12-21	1935-1940	would	_	_	_	_
12-22	1941-1943	be	_	_	_	_
12-23	1944-1952	occupied	_	_	_	_
12-24	1953-1954	;	_	_	_	_
12-25	1955-1964	therefore	abstract[93]	new[93]	_	_
12-26	1965-1968	the	abstract[93]	new[93]	_	_
12-27	1969-1977	presence	abstract[93]	new[93]	_	_
12-28	1978-1980	of	abstract[93]	new[93]	_	_
12-29	1981-1984	the	abstract[93]|substance[94]	new[93]|giv[94]	_	_
12-30	1985-2000	ammonium-ketone	abstract[93]|substance[94]	new[93]|giv[94]	_	_
12-31	2001-2005	form	abstract[93]|substance[94]	new[93]|giv[94]	_	_
12-32	2006-2008	in	abstract[93]|substance[94]	new[93]|giv[94]	_	_
12-33	2009-2012	the	abstract[93]|substance[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-34	2013-2020	crystal	abstract[93]|substance[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-35	2021-2030	structure	abstract[93]|substance[94]|abstract[95]	new[93]|giv[94]|giv[95]	_	_
12-36	2031-2035	does	_	_	_	_
12-37	2036-2039	not	_	_	_	_
12-38	2040-2051	necessarily	_	_	_	_
12-39	2052-2060	indicate	_	_	_	_
12-40	2061-2065	that	_	_	_	_
12-41	2066-2070	this	substance[96]	new[96]	coref	18-11[138_96]
12-42	2071-2075	form	substance[96]	new[96]	_	_
12-43	2076-2078	of	substance[96]	new[96]	_	_
12-44	2079-2089	anabaseine	substance[96]|substance	new[96]|giv	coref	12-56
12-45	2090-2095	would	_	_	_	_
12-46	2096-2100	bind	_	_	_	_
12-47	2101-2103	to	_	_	_	_
12-48	2104-2110	AChBPs	abstract	new	_	_
12-49	2111-2114	and	_	_	_	_
12-50	2115-2121	nAChRs	place	giv	coref	13-10[107_0]
12-51	2122-2124	at	_	_	_	_
12-52	2125-2128	the	quantity[100]	new[100]	_	_
12-53	2129-2132	low	quantity[100]	new[100]	_	_
12-54	2133-2147	concentrations	quantity[100]	new[100]	_	_
12-55	2148-2150	of	quantity[100]	new[100]	_	_
12-56	2151-2161	anabaseine	quantity[100]|substance	new[100]|giv	coref	17-37
12-57	2162-2166	that	_	_	_	_
12-58	2167-2172	occur	_	_	_	_
12-59	2173-2175	in	_	_	_	_
12-60	2176-2179	our	person|event[103]	giv|new[103]	ana|coref|ana|coref	16-1|26-20[184_103]|16-1|26-20[184_103]
12-61	2180-2182	in	event[103]	new[103]	_	_
12-62	2183-2188	vitro	event[103]	new[103]	_	_
12-63	2189-2199	functional	event[103]	new[103]	_	_
12-64	2200-2203	and	event[103]	new[103]	_	_
12-65	2204-2211	binding	event[103]	new[103]	_	_
12-66	2212-2219	studies	event[103]	new[103]	_	_
12-67	2220-2221	.	_	_	_	_

#Text=The ability of a variety of 2-(aryl)-1,4,5,6-tetrahydropyrmidines to block neuromuscular nAChRs and produce teratogenic effects in chick embryos was reported long ago .
13-1	2222-2225	The	abstract[104]	new[104]	_	_
13-2	2226-2233	ability	abstract[104]	new[104]	_	_
13-3	2234-2236	of	abstract[104]	new[104]	_	_
13-4	2237-2238	a	abstract[104]|abstract[105]	new[104]|new[105]	ana	14-1[111_105]
13-5	2239-2246	variety	abstract[104]|abstract[105]	new[104]|new[105]	_	_
13-6	2247-2249	of	abstract[104]|abstract[105]	new[104]|new[105]	_	_
13-7	2250-2287	2-(aryl)-1,4,5,6-tetrahydropyrmidines	abstract[104]|abstract[105]|abstract	new[104]|new[105]|new	_	_
13-8	2288-2290	to	_	_	_	_
13-9	2291-2296	block	_	_	_	_
13-10	2297-2310	neuromuscular	place[107]	giv[107]	coref	16-16[126_107]
13-11	2311-2317	nAChRs	place[107]	giv[107]	_	_
13-12	2318-2321	and	_	_	_	_
13-13	2322-2329	produce	_	_	_	_
13-14	2330-2341	teratogenic	abstract[108]	new[108]	_	_
13-15	2342-2349	effects	abstract[108]	new[108]	_	_
13-16	2350-2352	in	abstract[108]	new[108]	_	_
13-17	2353-2358	chick	abstract[108]|animal|object[110]	new[108]|new|new[110]	_	_
13-18	2359-2366	embryos	abstract[108]|object[110]	new[108]|new[110]	_	_
13-19	2367-2370	was	_	_	_	_
13-20	2371-2379	reported	_	_	_	_
13-21	2380-2384	long	_	_	_	_
13-22	2385-2388	ago	_	_	_	_
13-23	2389-2390	.	_	_	_	_

#Text=Some of these compounds were reported to be nAChR agonists .
14-1	2391-2395	Some	abstract[111]	giv[111]	_	_
14-2	2396-2398	of	abstract[111]	giv[111]	_	_
14-3	2399-2404	these	abstract[111]|substance[112]	giv[111]|new[112]	coref	17-1[127_112]
14-4	2405-2414	compounds	abstract[111]|substance[112]	giv[111]|new[112]	_	_
14-5	2415-2419	were	_	_	_	_
14-6	2420-2428	reported	_	_	_	_
14-7	2429-2431	to	_	_	_	_
14-8	2432-2434	be	_	_	_	_
14-9	2435-2440	nAChR	abstract|abstract[114]	giv|giv[114]	coref|coref	24-33|24-33
14-10	2441-2449	agonists	abstract[114]	giv[114]	_	_
14-11	2450-2451	.	_	_	_	_

#Text=The only study of PTHP on neurons was that of Upshall et al. on leech Retzius cells .
15-1	2452-2455	The	abstract[115]	new[115]	coref	17-6[128_115]
15-2	2456-2460	only	abstract[115]	new[115]	_	_
15-3	2461-2466	study	abstract[115]	new[115]	_	_
15-4	2467-2469	of	abstract[115]	new[115]	_	_
15-5	2470-2474	PTHP	abstract[115]|abstract[116]	new[115]|new[116]	coref	16-6[0_116]
15-6	2475-2477	on	abstract[115]|abstract[116]	new[115]|new[116]	_	_
15-7	2478-2485	neurons	abstract[115]|abstract[116]|object	new[115]|new[116]|new	_	_
15-8	2486-2489	was	_	_	_	_
15-9	2490-2494	that	_	_	_	_
15-10	2495-2497	of	_	_	_	_
15-11	2498-2505	Upshall	person	new	_	_
15-12	2506-2508	et	_	_	_	_
15-13	2509-2512	al.	_	_	_	_
15-14	2513-2515	on	_	_	_	_
15-15	2516-2521	leech	person|object[120]	new|new[120]	_	_
15-16	2522-2529	Retzius	object[120]	new[120]	_	_
15-17	2530-2535	cells	object[120]	new[120]	_	_
15-18	2536-2537	.	_	_	_	_

#Text=Our results also indicate that PTHP is a potent agonist at neuronal as well as neuromuscular nAChRs .
16-1	2538-2541	Our	person|abstract[122]	giv|new[122]	_	_
16-2	2542-2549	results	abstract[122]	new[122]	_	_
16-3	2550-2554	also	_	_	_	_
16-4	2555-2563	indicate	_	_	_	_
16-5	2564-2568	that	_	_	_	_
16-6	2569-2573	PTHP	abstract	giv	coref	16-8[124_0]
16-7	2574-2576	is	_	_	_	_
16-8	2577-2578	a	abstract[124]	giv[124]	coref	18-2[135_124]
16-9	2579-2585	potent	abstract[124]	giv[124]	_	_
16-10	2586-2593	agonist	abstract[124]	giv[124]	_	_
16-11	2594-2596	at	abstract[124]	giv[124]	_	_
16-12	2597-2605	neuronal	abstract[124]|person	giv[124]|new	ana	29-1
16-13	2606-2608	as	abstract[124]	giv[124]	_	_
16-14	2609-2613	well	abstract[124]	giv[124]	_	_
16-15	2614-2616	as	abstract[124]	giv[124]	_	_
16-16	2617-2630	neuromuscular	abstract[124]|abstract[126]	giv[124]|giv[126]	coref	26-3[181_126]
16-17	2631-2637	nAChRs	abstract[124]|abstract[126]	giv[124]|giv[126]	_	_
16-18	2638-2639	.	_	_	_	_

#Text=The 2-aryl compounds reported in the Brimblecombe et al. study did not include PTHP or other compounds having a 2-(3-pyridyl)- substituent , which is known to be essential for the agonist activity of nicotine and of anabaseine .
17-1	2640-2643	The	substance[127]	giv[127]	coref	17-14[129_127]
17-2	2644-2650	2-aryl	substance[127]	giv[127]	_	_
17-3	2651-2660	compounds	substance[127]	giv[127]	_	_
17-4	2661-2669	reported	_	_	_	_
17-5	2670-2672	in	_	_	_	_
17-6	2673-2676	the	abstract[128]	giv[128]	_	_
17-7	2677-2689	Brimblecombe	abstract[128]	giv[128]	_	_
17-8	2690-2692	et	abstract[128]	giv[128]	_	_
17-9	2693-2696	al.	abstract[128]	giv[128]	_	_
17-10	2697-2702	study	abstract[128]	giv[128]	_	_
17-11	2703-2706	did	_	_	_	_
17-12	2707-2710	not	_	_	_	_
17-13	2711-2718	include	_	_	_	_
17-14	2719-2723	PTHP	substance[129]	giv[129]	_	_
17-15	2724-2726	or	substance[129]	giv[129]	_	_
17-16	2727-2732	other	substance[129]	giv[129]	_	_
17-17	2733-2742	compounds	substance[129]	giv[129]	_	_
17-18	2743-2749	having	_	_	_	_
17-19	2750-2751	a	substance[130]	new[130]	_	_
17-20	2752-2766	2-(3-pyridyl)-	substance[130]	new[130]	_	_
17-21	2767-2778	substituent	substance[130]	new[130]	_	_
17-22	2779-2780	,	_	_	_	_
17-23	2781-2786	which	_	_	_	_
17-24	2787-2789	is	_	_	_	_
17-25	2790-2795	known	_	_	_	_
17-26	2796-2798	to	_	_	_	_
17-27	2799-2801	be	_	_	_	_
17-28	2802-2811	essential	_	_	_	_
17-29	2812-2815	for	_	_	_	_
17-30	2816-2819	the	abstract[132]	new[132]	coref	27-5[189_132]
17-31	2820-2827	agonist	person|abstract[132]	new|new[132]	_	_
17-32	2828-2836	activity	abstract[132]	new[132]	_	_
17-33	2837-2839	of	abstract[132]	new[132]	_	_
17-34	2840-2848	nicotine	abstract[132]|substance	new[132]|new	_	_
17-35	2849-2852	and	_	_	_	_
17-36	2853-2855	of	_	_	_	_
17-37	2856-2866	anabaseine	substance	giv	coref	18-7
17-38	2867-2868	.	_	_	_	_

#Text=For PTHP to be equipotent with anabaseine , based on the I+ form being the only active form , its EC50 would need to be ~1/3 of the EC50 of anabaseine , since the anabaseine ( I+ ) is ~1/3 of its total concentration .
18-1	2869-2872	For	_	_	_	_
18-2	2873-2877	PTHP	abstract[135]	giv[135]	coref	19-4[150_135]
18-3	2878-2880	to	abstract[135]	giv[135]	_	_
18-4	2881-2883	be	abstract[135]	giv[135]	_	_
18-5	2884-2894	equipotent	abstract[135]	giv[135]	_	_
18-6	2895-2899	with	_	_	_	_
18-7	2900-2910	anabaseine	substance	giv	ana	18-20
18-8	2911-2912	,	_	_	_	_
18-9	2913-2918	based	_	_	_	_
18-10	2919-2921	on	_	_	_	_
18-11	2922-2925	the	substance[138]	giv[138]	coref	18-15[139_138]
18-12	2926-2928	I+	object|substance[138]	new|giv[138]	appos	18-37
18-13	2929-2933	form	substance[138]	giv[138]	_	_
18-14	2934-2939	being	_	_	_	_
18-15	2940-2943	the	substance[139]	giv[139]	coref	23-18[159_139]
18-16	2944-2948	only	substance[139]	giv[139]	_	_
18-17	2949-2955	active	substance[139]	giv[139]	_	_
18-18	2956-2960	form	substance[139]	giv[139]	_	_
18-19	2961-2962	,	_	_	_	_
18-20	2963-2966	its	substance|abstract[141]	giv|new[141]	coref|coref|coref|coref	18-28[143_141]|18-31|18-28[143_141]|18-31
18-21	2967-2971	EC50	abstract[141]	new[141]	_	_
18-22	2972-2977	would	_	_	_	_
18-23	2978-2982	need	_	_	_	_
18-24	2983-2985	to	_	_	_	_
18-25	2986-2988	be	_	_	_	_
18-26	2989-2993	~1/3	quantity[142]	new[142]	_	_
18-27	2994-2996	of	quantity[142]	new[142]	_	_
18-28	2997-3000	the	quantity[142]|abstract[143]	new[142]|giv[143]	_	_
18-29	3001-3005	EC50	quantity[142]|abstract[143]	new[142]|giv[143]	_	_
18-30	3006-3008	of	quantity[142]|abstract[143]	new[142]|giv[143]	_	_
18-31	3009-3019	anabaseine	quantity[142]|abstract[143]|substance	new[142]|giv[143]|giv	coref	18-34[145_0]
18-32	3020-3021	,	_	_	_	_
18-33	3022-3027	since	_	_	_	_
18-34	3028-3031	the	substance[145]	giv[145]	ana	18-42[0_145]
18-35	3032-3042	anabaseine	substance[145]	giv[145]	_	_
18-36	3043-3044	(	_	_	_	_
18-37	3045-3047	I+	abstract	giv	_	_
18-38	3048-3049	)	_	_	_	_
18-39	3050-3052	is	_	_	_	_
18-40	3053-3057	~1/3	_	_	_	_
18-41	3058-3060	of	_	_	_	_
18-42	3061-3064	its	substance|abstract[148]	giv|new[148]	coref|coref|coref|coref	19-6[151_0]|34-33[238_148]|19-6[151_0]|34-33[238_148]
18-43	3065-3070	total	abstract[148]	new[148]	_	_
18-44	3071-3084	concentration	abstract[148]	new[148]	_	_
18-45	3085-3086	.	_	_	_	_

#Text=The data for PTHP and anabaseine in
19-1	3087-3090	The	abstract[149]	new[149]	_	_
19-2	3091-3095	data	abstract[149]	new[149]	_	_
19-3	3096-3099	for	abstract[149]	new[149]	_	_
19-4	3100-3104	PTHP	abstract[149]|abstract[150]	new[149]|giv[150]	coref	23-8[0_150]
19-5	3105-3108	and	abstract[149]|abstract[150]	new[149]|giv[150]	_	_
19-6	3109-3119	anabaseine	abstract[149]|abstract[150]|substance[151]	new[149]|giv[150]|giv[151]	coref	29-32[0_151]
19-7	3120-3122	in	abstract[149]|abstract[150]|substance[151]	new[149]|giv[150]|giv[151]	_	_

#Text=Figure 3
20-1	3123-3129	Figure	abstract[152]	new[152]	_	_
20-2	3130-3131	3	abstract[152]	new[152]	_	_

#Text=and
21-1	3132-3135	and	_	_	_	_

#Text=Figure 4
22-1	3136-3142	Figure	abstract[153]	new[153]	_	_
22-2	3143-3144	4	abstract[153]	new[153]	_	_

#Text=and in Table 1 , indicate that PTHP has approximately 30 % of the potency predicted for the anabaseine cyclic iminium form .
23-1	3145-3148	and	_	_	_	_
23-2	3149-3151	in	_	_	_	_
23-3	3152-3157	Table	object[154]	new[154]	_	_
23-4	3158-3159	1	object[154]	new[154]	_	_
23-5	3160-3161	,	_	_	_	_
23-6	3162-3170	indicate	_	_	_	_
23-7	3171-3175	that	_	_	_	_
23-8	3176-3180	PTHP	object	giv	_	_
23-9	3181-3184	has	_	_	_	_
23-10	3185-3198	approximately	quantity[156]	new[156]	_	_
23-11	3199-3201	30	quantity[156]	new[156]	_	_
23-12	3202-3203	%	quantity[156]	new[156]	_	_
23-13	3204-3206	of	quantity[156]	new[156]	_	_
23-14	3207-3210	the	quantity[156]|abstract[157]	new[156]|giv[157]	coref	24-5[161_157]
23-15	3211-3218	potency	quantity[156]|abstract[157]	new[156]|giv[157]	_	_
23-16	3219-3228	predicted	_	_	_	_
23-17	3229-3232	for	_	_	_	_
23-18	3233-3236	the	substance[159]	giv[159]	coref	28-11[195_159]
23-19	3237-3247	anabaseine	substance[159]	giv[159]	_	_
23-20	3248-3254	cyclic	substance[159]	giv[159]	_	_
23-21	3255-3262	iminium	object|substance[159]	giv|giv[159]	_	_
23-22	3263-3267	form	substance[159]	giv[159]	_	_
23-23	3268-3269	.	_	_	_	_

#Text=One possible explanation for this slightly inferior potency is that the additional N on the tetrahydropyrmidinyl ring must form an H bond with some other atom within the aromatic box of the nAChR orthosteric binding site and this may be energetically unfavorable .
24-1	3270-3273	One	abstract[160]	new[160]	_	_
24-2	3274-3282	possible	abstract[160]	new[160]	_	_
24-3	3283-3294	explanation	abstract[160]	new[160]	_	_
24-4	3295-3298	for	abstract[160]	new[160]	_	_
24-5	3299-3303	this	abstract[160]|abstract[161]	new[160]|giv[161]	coref	25-4[174_161]
24-6	3304-3312	slightly	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
24-7	3313-3321	inferior	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
24-8	3322-3329	potency	abstract[160]|abstract[161]	new[160]|giv[161]	_	_
24-9	3330-3332	is	_	_	_	_
24-10	3333-3337	that	_	_	_	_
24-11	3338-3341	the	abstract[162]	new[162]	_	_
24-12	3342-3352	additional	abstract[162]	new[162]	_	_
24-13	3353-3354	N	abstract[162]	new[162]	_	_
24-14	3355-3357	on	abstract[162]	new[162]	_	_
24-15	3358-3361	the	abstract[162]|object[164]	new[162]|giv[164]	_	_
24-16	3362-3382	tetrahydropyrmidinyl	abstract[162]|abstract|object[164]	new[162]|new|giv[164]	_	_
24-17	3383-3387	ring	abstract[162]|object[164]	new[162]|giv[164]	_	_
24-18	3388-3392	must	_	_	_	_
24-19	3393-3397	form	_	_	_	_
24-20	3398-3400	an	abstract[166]	giv[166]	coref	34-7[231_166]
24-21	3401-3402	H	person|abstract[166]	new|giv[166]	_	_
24-22	3403-3407	bond	abstract[166]	giv[166]	_	_
24-23	3408-3412	with	_	_	_	_
24-24	3413-3417	some	substance[167]	new[167]	_	_
24-25	3418-3423	other	substance[167]	new[167]	_	_
24-26	3424-3428	atom	substance[167]	new[167]	_	_
24-27	3429-3435	within	_	_	_	_
24-28	3436-3439	the	object[168]	giv[168]	ana	24-38[0_168]
24-29	3440-3448	aromatic	object[168]	giv[168]	_	_
24-30	3449-3452	box	object[168]	giv[168]	_	_
24-31	3453-3455	of	object[168]	giv[168]	_	_
24-32	3456-3459	the	object[168]|place[171]	giv[168]|giv[171]	coref	34-16[234_171]
24-33	3460-3465	nAChR	object[168]|abstract|place[171]	giv[168]|giv|giv[171]	coref	34-17
24-34	3466-3477	orthosteric	object[168]|place[171]	giv[168]|giv[171]	_	_
24-35	3478-3485	binding	object[168]|object|place[171]	giv[168]|giv|giv[171]	_	_
24-36	3486-3490	site	object[168]|place[171]	giv[168]|giv[171]	_	_
24-37	3491-3494	and	_	_	_	_
24-38	3495-3499	this	object	giv	_	_
24-39	3500-3503	may	_	_	_	_
24-40	3504-3506	be	_	_	_	_
24-41	3507-3520	energetically	_	_	_	_
24-42	3521-3532	unfavorable	_	_	_	_
24-43	3533-3534	.	_	_	_	_

#Text=While 2,3′-bipyridyl displayed only a marginal potency at vertebrate receptors that could be predicted from its pKa , it has been found to be quite paralytic to insects and crustaceans .
25-1	3535-3540	While	_	_	_	_
25-2	3541-3555	2,3′-bipyridyl	organization	new	coref	28-5
25-3	3556-3565	displayed	_	_	_	_
25-4	3566-3570	only	abstract[174]	giv[174]	ana	25-16[0_174]
25-5	3571-3572	a	abstract[174]	giv[174]	_	_
25-6	3573-3581	marginal	abstract[174]	giv[174]	_	_
25-7	3582-3589	potency	abstract[174]	giv[174]	_	_
25-8	3590-3592	at	abstract[174]	giv[174]	_	_
25-9	3593-3603	vertebrate	abstract[174]|event[175]	giv[174]|new[175]	_	_
25-10	3604-3613	receptors	abstract[174]|event[175]	giv[174]|new[175]	_	_
25-11	3614-3618	that	_	_	_	_
25-12	3619-3624	could	_	_	_	_
25-13	3625-3627	be	_	_	_	_
25-14	3628-3637	predicted	_	_	_	_
25-15	3638-3642	from	_	_	_	_
25-16	3643-3646	its	abstract|abstract[177]	giv|new[177]	ana|ana	25-19|25-19
25-17	3647-3650	pKa	abstract[177]	new[177]	_	_
25-18	3651-3652	,	_	_	_	_
25-19	3653-3655	it	abstract	giv	_	_
25-20	3656-3659	has	_	_	_	_
25-21	3660-3664	been	_	_	_	_
25-22	3665-3670	found	_	_	_	_
25-23	3671-3673	to	_	_	_	_
25-24	3674-3676	be	_	_	_	_
25-25	3677-3682	quite	_	_	_	_
25-26	3683-3692	paralytic	_	_	_	_
25-27	3693-3695	to	_	_	_	_
25-28	3696-3703	insects	animal	new	_	_
25-29	3704-3707	and	_	_	_	_
25-30	3708-3719	crustaceans	animal	new	_	_
25-31	3720-3721	.	_	_	_	_

#Text=At least some arthropod nAChRs are known to not require a cationic ligand for activation , as shown by many studies with neonicotinoid insecticides such as imidachloprid .
26-1	3722-3724	At	_	_	_	_
26-2	3725-3730	least	_	_	_	_
26-3	3731-3735	some	abstract[181]	giv[181]	coref	27-9[190_181]
26-4	3736-3745	arthropod	abstract[181]	giv[181]	_	_
26-5	3746-3752	nAChRs	abstract[181]	giv[181]	_	_
26-6	3753-3756	are	_	_	_	_
26-7	3757-3762	known	_	_	_	_
26-8	3763-3765	to	_	_	_	_
26-9	3766-3769	not	_	_	_	_
26-10	3770-3777	require	_	_	_	_
26-11	3778-3779	a	substance[182]	new[182]	_	_
26-12	3780-3788	cationic	substance[182]	new[182]	_	_
26-13	3789-3795	ligand	substance[182]	new[182]	_	_
26-14	3796-3799	for	substance[182]	new[182]	_	_
26-15	3800-3810	activation	substance[182]|event	new[182]|new	_	_
26-16	3811-3812	,	_	_	_	_
26-17	3813-3815	as	_	_	_	_
26-18	3816-3821	shown	_	_	_	_
26-19	3822-3824	by	_	_	_	_
26-20	3825-3829	many	event[184]	giv[184]	_	_
26-21	3830-3837	studies	event[184]	giv[184]	_	_
26-22	3838-3842	with	event[184]	giv[184]	_	_
26-23	3843-3856	neonicotinoid	event[184]|object|animal[186]	giv[184]|new|new[186]	_	_
26-24	3857-3869	insecticides	event[184]|animal[186]	giv[184]|new[186]	_	_
26-25	3870-3874	such	event[184]|animal[186]	giv[184]|new[186]	_	_
26-26	3875-3877	as	event[184]|animal[186]	giv[184]|new[186]	_	_
26-27	3878-3891	imidachloprid	event[184]|animal[186]|substance	giv[184]|new[186]|new	_	_
26-28	3892-3893	.	_	_	_	_

#Text=These neonicotinoids also display a limited activity at vertebrate nAChRs .
27-1	3894-3899	These	substance[188]	new[188]	_	_
27-2	3900-3914	neonicotinoids	substance[188]	new[188]	_	_
27-3	3915-3919	also	_	_	_	_
27-4	3920-3927	display	_	_	_	_
27-5	3928-3929	a	abstract[189]	giv[189]	_	_
27-6	3930-3937	limited	abstract[189]	giv[189]	_	_
27-7	3938-3946	activity	abstract[189]	giv[189]	_	_
27-8	3947-3949	at	abstract[189]	giv[189]	_	_
27-9	3950-3960	vertebrate	abstract[189]|place[190]	giv[189]|giv[190]	ana	28-1[0_190]
27-10	3961-3967	nAChRs	abstract[189]|place[190]	giv[189]|giv[190]	_	_
27-11	3968-3969	.	_	_	_	_

#Text=It seems likely that 2,3′-bipyridyl affects some arthropod nAChRs through its unionized form .
28-1	3970-3972	It	place	giv	coref	28-7[193_0]
28-2	3973-3978	seems	_	_	_	_
28-3	3979-3985	likely	_	_	_	_
28-4	3986-3990	that	_	_	_	_
28-5	3991-4005	2,3′-bipyridyl	abstract	giv	_	_
28-6	4006-4013	affects	_	_	_	_
28-7	4014-4018	some	abstract[193]	giv[193]	ana	28-11[0_193]
28-8	4019-4028	arthropod	abstract[193]	giv[193]	_	_
28-9	4029-4035	nAChRs	abstract[193]	giv[193]	_	_
28-10	4036-4043	through	_	_	_	_
28-11	4044-4047	its	place|substance[195]	giv|giv[195]	coref|coref	34-28[237_195]|34-28[237_195]
28-12	4048-4057	unionized	substance[195]	giv[195]	_	_
28-13	4058-4062	form	substance[195]	giv[195]	_	_
28-14	4063-4064	.	_	_	_	_

#Text=One can speculate as to what advantage(s) might accrue to an organism ( in this case , a hoplonemertine or ant ) to produce and secrete an imine-bond containing toxin like anabaseine .
29-1	4065-4068	One	person	giv	_	_
29-2	4069-4072	can	_	_	_	_
29-3	4073-4082	speculate	_	_	_	_
29-4	4083-4085	as	_	_	_	_
29-5	4086-4088	to	_	_	_	_
29-6	4089-4093	what	_	_	_	_
29-7	4094-4106	advantage(s)	abstract	new	_	_
29-8	4107-4112	might	_	_	_	_
29-9	4113-4119	accrue	_	_	_	_
29-10	4120-4122	to	_	_	_	_
29-11	4123-4125	an	animal[198]	new[198]	coref	35-4[247_198]
29-12	4126-4134	organism	animal[198]	new[198]	_	_
29-13	4135-4136	(	_	_	_	_
29-14	4137-4139	in	_	_	_	_
29-15	4140-4144	this	abstract[199]	new[199]	_	_
29-16	4145-4149	case	abstract[199]	new[199]	_	_
29-17	4150-4151	,	_	_	_	_
29-18	4152-4153	a	animal[200]	new[200]	_	_
29-19	4154-4168	hoplonemertine	animal[200]	new[200]	_	_
29-20	4169-4171	or	_	_	_	_
29-21	4172-4175	ant	animal	new	_	_
29-22	4176-4177	)	_	_	_	_
29-23	4178-4180	to	_	_	_	_
29-24	4181-4188	produce	_	_	_	_
29-25	4189-4192	and	_	_	_	_
29-26	4193-4200	secrete	_	_	_	_
29-27	4201-4203	an	substance[202]	new[202]	_	_
29-28	4204-4214	imine-bond	substance[202]	new[202]	_	_
29-29	4215-4225	containing	_	_	_	_
29-30	4226-4231	toxin	substance[203]	new[203]	coref	36-3[255_203]
29-31	4232-4236	like	substance[203]	new[203]	_	_
29-32	4237-4247	anabaseine	substance[203]|substance	new[203]|giv	coref	30-24
29-33	4248-4249	.	_	_	_	_

#Text=The entire body wall integument as well as the contiguous epithelium of the anterior proboscis of P. peregrina contains very high concentrations of anabaseine .
30-1	4250-4253	The	abstract[207]	new[207]	coref	32-15[224_207]
30-2	4254-4260	entire	abstract[207]	new[207]	_	_
30-3	4261-4265	body	object|abstract[207]	new|new[207]	_	_
30-4	4266-4270	wall	object|abstract[207]	new|new[207]	_	_
30-5	4271-4281	integument	abstract[207]	new[207]	_	_
30-6	4282-4284	as	_	_	_	_
30-7	4285-4289	well	_	_	_	_
30-8	4290-4292	as	_	_	_	_
30-9	4293-4296	the	place[208]	new[208]	coref	31-16[217_208]
30-10	4297-4307	contiguous	place[208]	new[208]	_	_
30-11	4308-4318	epithelium	place[208]	new[208]	_	_
30-12	4319-4321	of	place[208]	new[208]	_	_
30-13	4322-4325	the	place[208]|object[209]	new[208]|new[209]	coref	31-1[212_209]
30-14	4326-4334	anterior	place[208]|object[209]	new[208]|new[209]	_	_
30-15	4335-4344	proboscis	place[208]|object[209]	new[208]|new[209]	_	_
30-16	4345-4347	of	place[208]|object[209]	new[208]|new[209]	_	_
30-17	4348-4350	P.	place[208]|object[209]	new[208]|new[209]	_	_
30-18	4351-4360	peregrina	place[208]|object[209]	new[208]|new[209]	_	_
30-19	4361-4369	contains	_	_	_	_
30-20	4370-4374	very	animal[210]	giv[210]	_	_
30-21	4375-4379	high	animal[210]	giv[210]	_	_
30-22	4380-4394	concentrations	animal[210]	giv[210]	_	_
30-23	4395-4397	of	animal[210]	giv[210]	_	_
30-24	4398-4408	anabaseine	animal[210]|substance	giv[210]|giv	coref	35-27
30-25	4409-4410	.	_	_	_	_

#Text=The proboscis everts and wraps around the prey during its capture allowing extensive contact of this epithelium with its annelid prey .
31-1	4411-4414	The	object[212]	giv[212]	coref	32-5[221_212]
31-2	4415-4424	proboscis	object[212]	giv[212]	_	_
31-3	4425-4431	everts	_	_	_	_
31-4	4432-4435	and	_	_	_	_
31-5	4436-4441	wraps	_	_	_	_
31-6	4442-4448	around	_	_	_	_
31-7	4449-4452	the	animal[213]	new[213]	ana	31-10[0_213]
31-8	4453-4457	prey	animal[213]	new[213]	_	_
31-9	4458-4464	during	_	_	_	_
31-10	4465-4468	its	animal|event[215]	giv|new[215]	coref|coref	31-19[219_0]|31-19[219_0]
31-11	4469-4476	capture	event[215]	new[215]	_	_
31-12	4477-4485	allowing	_	_	_	_
31-13	4486-4495	extensive	abstract[216]	new[216]	_	_
31-14	4496-4503	contact	abstract[216]	new[216]	_	_
31-15	4504-4506	of	abstract[216]	new[216]	_	_
31-16	4507-4511	this	abstract[216]|place[217]	new[216]|giv[217]	_	_
31-17	4512-4522	epithelium	abstract[216]|place[217]	new[216]|giv[217]	_	_
31-18	4523-4527	with	abstract[216]|place[217]	new[216]|giv[217]	_	_
31-19	4528-4531	its	abstract[216]|place[217]|animal[219]	new[216]|giv[217]|giv[219]	coref	32-16[0_219]
31-20	4532-4539	annelid	abstract[216]|place[217]|animal|animal[219]	new[216]|giv[217]|new|giv[219]	_	_
31-21	4540-4544	prey	abstract[216]|place[217]|animal[219]	new[216]|giv[217]|giv[219]	_	_
31-22	4545-4546	.	_	_	_	_

#Text=The mineralized stylet of the proboscis can be observed to produce multiple punctures of the prey integument , which should further facilitate envenomation .
32-1	4547-4550	The	abstract[220]	new[220]	_	_
32-2	4551-4562	mineralized	abstract[220]	new[220]	_	_
32-3	4563-4569	stylet	abstract[220]	new[220]	_	_
32-4	4570-4572	of	abstract[220]	new[220]	_	_
32-5	4573-4576	the	abstract[220]|object[221]	new[220]|giv[221]	_	_
32-6	4577-4586	proboscis	abstract[220]|object[221]	new[220]|giv[221]	_	_
32-7	4587-4590	can	_	_	_	_
32-8	4591-4593	be	_	_	_	_
32-9	4594-4602	observed	_	_	_	_
32-10	4603-4605	to	_	_	_	_
32-11	4606-4613	produce	_	_	_	_
32-12	4614-4622	multiple	abstract[222]	new[222]	_	_
32-13	4623-4632	punctures	abstract[222]	new[222]	_	_
32-14	4633-4635	of	abstract[222]	new[222]	_	_
32-15	4636-4639	the	abstract[222]|abstract[224]	new[222]|giv[224]	coref	34-52[243_224]
32-16	4640-4644	prey	abstract[222]|animal|abstract[224]	new[222]|giv|giv[224]	coref	34-55[244_0]
32-17	4645-4655	integument	abstract[222]|abstract[224]	new[222]|giv[224]	_	_
32-18	4656-4657	,	_	_	_	_
32-19	4658-4663	which	_	_	_	_
32-20	4664-4670	should	_	_	_	_
32-21	4671-4678	further	_	_	_	_
32-22	4679-4689	facilitate	_	_	_	_
32-23	4690-4702	envenomation	event	new	_	_
32-24	4703-4704	.	_	_	_	_

#Text=In addition , potential predators will also be exposed in these ways to anabaseine and related alkaloids .
33-1	4705-4707	In	_	_	_	_
33-2	4708-4716	addition	_	_	_	_
33-3	4717-4718	,	_	_	_	_
33-4	4719-4728	potential	person[226]	new[226]	_	_
33-5	4729-4738	predators	person[226]	new[226]	_	_
33-6	4739-4743	will	_	_	_	_
33-7	4744-4748	also	_	_	_	_
33-8	4749-4751	be	_	_	_	_
33-9	4752-4759	exposed	_	_	_	_
33-10	4760-4762	in	_	_	_	_
33-11	4763-4768	these	abstract[227]	new[227]	_	_
33-12	4769-4773	ways	abstract[227]	new[227]	_	_
33-13	4774-4776	to	abstract[227]	new[227]	_	_
33-14	4777-4787	anabaseine	abstract[227]|substance[228]	new[227]|new[228]	_	_
33-15	4788-4791	and	abstract[227]|substance[228]	new[227]|new[228]	_	_
33-16	4792-4799	related	abstract[227]|substance[228]	new[227]|new[228]	_	_
33-17	4800-4809	alkaloids	abstract[227]|substance[228]	new[227]|new[228]	_	_
33-18	4810-4811	.	_	_	_	_

#Text=Perhaps a major advantage of possessing an imine bond , besides an enhanced affinity for the nAChR orthosteric site , is its low basicity , which allows the unionized form to reach a relatively high concentration in the neutral pH range of the marine environment and thereby enhance passive diffusion across the integument of the prey or predator .
34-1	4812-4819	Perhaps	abstract[229]	new[229]	_	_
34-2	4820-4821	a	abstract[229]	new[229]	_	_
34-3	4822-4827	major	abstract[229]	new[229]	_	_
34-4	4828-4837	advantage	abstract[229]	new[229]	_	_
34-5	4838-4840	of	_	_	_	_
34-6	4841-4851	possessing	_	_	_	_
34-7	4852-4854	an	abstract[231]	giv[231]	_	_
34-8	4855-4860	imine	abstract|abstract[231]	new|giv[231]	_	_
34-9	4861-4865	bond	abstract[231]	giv[231]	_	_
34-10	4866-4867	,	_	_	_	_
34-11	4868-4875	besides	_	_	_	_
34-12	4876-4878	an	abstract[232]	new[232]	ana	34-22[0_232]
34-13	4879-4887	enhanced	abstract[232]	new[232]	_	_
34-14	4888-4896	affinity	abstract[232]	new[232]	_	_
34-15	4897-4900	for	abstract[232]	new[232]	_	_
34-16	4901-4904	the	abstract[232]|place[234]	new[232]|giv[234]	_	_
34-17	4905-4910	nAChR	abstract[232]|abstract|place[234]	new[232]|giv|giv[234]	_	_
34-18	4911-4922	orthosteric	abstract[232]|place[234]	new[232]|giv[234]	_	_
34-19	4923-4927	site	abstract[232]|place[234]	new[232]|giv[234]	_	_
34-20	4928-4929	,	_	_	_	_
34-21	4930-4932	is	_	_	_	_
34-22	4933-4936	its	abstract|abstract[236]	giv|new[236]	_	_
34-23	4937-4940	low	abstract[236]	new[236]	_	_
34-24	4941-4949	basicity	abstract[236]	new[236]	_	_
34-25	4950-4951	,	_	_	_	_
34-26	4952-4957	which	_	_	_	_
34-27	4958-4964	allows	_	_	_	_
34-28	4965-4968	the	substance[237]	giv[237]	_	_
34-29	4969-4978	unionized	substance[237]	giv[237]	_	_
34-30	4979-4983	form	substance[237]	giv[237]	_	_
34-31	4984-4986	to	_	_	_	_
34-32	4987-4992	reach	_	_	_	_
34-33	4993-4994	a	abstract[238]	giv[238]	_	_
34-34	4995-5005	relatively	abstract[238]	giv[238]	_	_
34-35	5006-5010	high	abstract[238]	giv[238]	_	_
34-36	5011-5024	concentration	abstract[238]	giv[238]	_	_
34-37	5025-5027	in	abstract[238]	giv[238]	_	_
34-38	5028-5031	the	abstract[238]|abstract[240]	giv[238]|new[240]	coref	35-22[253_240]
34-39	5032-5039	neutral	abstract[238]|abstract[240]	giv[238]|new[240]	_	_
34-40	5040-5042	pH	abstract[238]|quantity|abstract[240]	giv[238]|new|new[240]	coref	35-15[250_0]
34-41	5043-5048	range	abstract[238]|abstract[240]	giv[238]|new[240]	_	_
34-42	5049-5051	of	abstract[238]|abstract[240]	giv[238]|new[240]	_	_
34-43	5052-5055	the	abstract[238]|abstract[240]|place[241]	giv[238]|new[240]|new[241]	_	_
34-44	5056-5062	marine	abstract[238]|abstract[240]|place[241]	giv[238]|new[240]|new[241]	_	_
34-45	5063-5074	environment	abstract[238]|abstract[240]|place[241]	giv[238]|new[240]|new[241]	_	_
34-46	5075-5078	and	_	_	_	_
34-47	5079-5086	thereby	_	_	_	_
34-48	5087-5094	enhance	_	_	_	_
34-49	5095-5102	passive	abstract[242]	new[242]	_	_
34-50	5103-5112	diffusion	abstract[242]	new[242]	_	_
34-51	5113-5119	across	abstract[242]	new[242]	_	_
34-52	5120-5123	the	abstract[242]|abstract[243]	new[242]|giv[243]	_	_
34-53	5124-5134	integument	abstract[242]|abstract[243]	new[242]|giv[243]	_	_
34-54	5135-5137	of	abstract[242]|abstract[243]	new[242]|giv[243]	_	_
34-55	5138-5141	the	abstract[242]|abstract[243]|animal[244]	new[242]|giv[243]|giv[244]	_	_
34-56	5142-5146	prey	abstract[242]|abstract[243]|animal[244]	new[242]|giv[243]|giv[244]	_	_
34-57	5147-5149	or	abstract[242]|abstract[243]	new[242]|giv[243]	_	_
34-58	5150-5158	predator	abstract[242]|abstract[243]|animal	new[242]|giv[243]|new	_	_
34-59	5159-5160	.	_	_	_	_

#Text=The integument of a marine organism exposed to sea water is likely to have a pH near 8 , well above the pH range in which anabaseine is primarily ionized .
35-1	5161-5164	The	substance[246]	new[246]	_	_
35-2	5165-5175	integument	substance[246]	new[246]	_	_
35-3	5176-5178	of	substance[246]	new[246]	_	_
35-4	5179-5180	a	substance[246]|animal[247]	new[246]|giv[247]	_	_
35-5	5181-5187	marine	substance[246]|animal[247]	new[246]|giv[247]	_	_
35-6	5188-5196	organism	substance[246]|animal[247]	new[246]|giv[247]	_	_
35-7	5197-5204	exposed	_	_	_	_
35-8	5205-5207	to	_	_	_	_
35-9	5208-5211	sea	place|substance[249]	new|new[249]	_	_
35-10	5212-5217	water	substance[249]	new[249]	_	_
35-11	5218-5220	is	_	_	_	_
35-12	5221-5227	likely	_	_	_	_
35-13	5228-5230	to	_	_	_	_
35-14	5231-5235	have	_	_	_	_
35-15	5236-5237	a	quantity[250]	giv[250]	coref	35-23[0_250]
35-16	5238-5240	pH	quantity[250]	giv[250]	_	_
35-17	5241-5245	near	quantity[250]	giv[250]	_	_
35-18	5246-5247	8	quantity[250]|quantity	giv[250]|new	_	_
35-19	5248-5249	,	_	_	_	_
35-20	5250-5254	well	_	_	_	_
35-21	5255-5260	above	_	_	_	_
35-22	5261-5264	the	abstract[253]	giv[253]	_	_
35-23	5265-5267	pH	quantity|abstract[253]	giv|giv[253]	_	_
35-24	5268-5273	range	abstract[253]	giv[253]	_	_
35-25	5274-5276	in	_	_	_	_
35-26	5277-5282	which	_	_	_	_
35-27	5283-5293	anabaseine	substance	giv	coref	36-25
35-28	5294-5296	is	_	_	_	_
35-29	5297-5306	primarily	_	_	_	_
35-30	5307-5314	ionized	_	_	_	_
35-31	5315-5316	.	_	_	_	_

#Text=Thus , the toxin has a much better chance of entering the prey/predator than would anabaseine , the more basic secondary amine analog of anabaseine .
36-1	5317-5321	Thus	_	_	_	_
36-2	5322-5323	,	_	_	_	_
36-3	5324-5327	the	substance[255]	giv[255]	_	_
36-4	5328-5333	toxin	substance[255]	giv[255]	_	_
36-5	5334-5337	has	_	_	_	_
36-6	5338-5339	a	abstract[256]	new[256]	_	_
36-7	5340-5344	much	abstract[256]	new[256]	_	_
36-8	5345-5351	better	abstract[256]	new[256]	_	_
36-9	5352-5358	chance	abstract[256]	new[256]	_	_
36-10	5359-5361	of	_	_	_	_
36-11	5362-5370	entering	_	_	_	_
36-12	5371-5374	the	_	_	_	_
36-13	5375-5388	prey/predator	_	_	_	_
36-14	5389-5393	than	_	_	_	_
36-15	5394-5399	would	_	_	_	_
36-16	5400-5410	anabaseine	_	_	_	_
36-17	5411-5412	,	_	_	_	_
36-18	5413-5416	the	substance[258]	new[258]	_	_
36-19	5417-5421	more	substance[258]	new[258]	_	_
36-20	5422-5427	basic	substance[258]	new[258]	_	_
36-21	5428-5437	secondary	substance[258]	new[258]	_	_
36-22	5438-5443	amine	abstract|substance[258]	new|new[258]	_	_
36-23	5444-5450	analog	substance[258]	new[258]	_	_
36-24	5451-5453	of	substance[258]	new[258]	_	_
36-25	5454-5464	anabaseine	substance[258]|substance	new[258]|giv	_	_
36-26	5465-5466	.	_	_	_	_
